ARL13A

Across TCGA pan-cancer cohorts, ARL13A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARL13A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARL13A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARL13A is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

HNSC, THCA, and STAD are the cancer types where ARL13A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL13A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.322	<.001	11	view →
THCA	All	II,III,IV	−0.287	<.001	7	view →
STAD	Male	All	+0.335	.007	4	view →
UCEC	All	All	−0.243	.001	4	view →
LUSC	Male	All	+0.182	.010	4	view →
KIRC	All	All	+0.094	.002	4	view →
CHOL	All	All	+0.490	<.001	3	view →
LIHC	All	All	+0.065	.001	3	view →
KIRP	Female	II,III,IV	+0.376	.018	2	view →
BRCA	All	III,IV	−0.183	.019	2	view →
READ	Female	All	+0.506	.031	1	view →
KICH	All	II,III,IV	+0.163	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARL13A–HNSC

Open the HNSC breakdown →